Gene activated matrix therapies - Selective Genetics

Drug Profile

Gene activated matrix therapies - Selective Genetics

Alternative Names: non-union fracture GAM therapy

Latest Information Update: 16 Mar 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selective Genetics (CEASED); University of Michigan Medical School
  • Developer Biomet; Selective Genetics (CEASED); University of Michigan Medical School
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-union fracture; Osteoporosis; Spinal cord injuries

Most Recent Events

  • 30 Sep 2006 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
  • 20 Jul 2006 Discontinued - Preclinical for Osteoporosis in USA (Intralesional)
  • 30 Apr 2006 Discontinued - Preclinical for Non-union fracture in USA (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top